Usually, exceeding expectations when it comes to a sales goal is a good thing. But in the case of Actavis ($ACT) and its forced switch of patients to a once-daily version of its Alzheimer's treatment Namenda, it is posing some problems--supply problems. The company announced earlier that it would stop production in August of the original version, a move that would leave patients no choice but to switch to the patent protected extended release product, and so keep most of the sales. It has since said it will continue to make it into the fall and conceded to Bloomberg that it is having trouble keeping up with demand for the new capsule. Story | More